Vanta Bioscience Ltd Stock Price Today (NSE: VANTABIO)
Vanta Bioscience Ltd
Fundamental Score
Vanta Bioscience Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vanta Bioscience Ltd share price today is ₹25.29, up +0.00% on NSE/BSE as of 3 August 2026. Vanta Bioscience Ltd (VANTABIO) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹17.99 (Cr). The 52-week high for VANTABIO share price is ₹29.00 and the 52-week low is ₹14.71. At a P/E ratio of 163.55x, VANTABIO is currently trading above its industry average P/E of 39.78x. The company has a Return on Equity (ROE) of 0.70% and a debt-to-equity ratio of 1.80.
Vanta Bioscience Ltd Share Price Chart — NSE/BSE Historical Performance
Vanta Bioscience Ltd share price chart: -0.25% return over the past month. 52-week high ₹29.00, 52-week low ₹14.71.
Vanta Bioscience Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹24.03 | ₹24.03 | ₹24.03 | ₹24.03 | 750.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 0.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 0.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 750.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 0.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 0.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 0.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 0.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 0.00 (Cr) | |
| ₹25.29 | ₹25.29 | ₹25.29 | ₹25.29 | 0.00 (Cr) |
Vanta Bioscience Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹24.09 | ₹25.29 | ₹24.03 | ₹24.03 | -0.25% | |
| ₹23.23 | ₹25.85 | ₹22.00 | ₹24.09 | +3.70% | |
| ₹18.30 | ₹24.45 | ₹15.58 | ₹23.23 | +26.94% | |
| ₹17.95 | ₹18.50 | ₹15.20 | ₹16.25 | -9.47% | |
| ₹15.05 | ₹20.60 | ₹14.71 | ₹15.15 | +0.66% | |
| ₹19.89 | ₹23.00 | ₹16.26 | ₹18.60 | -6.49% | |
| ₹22.25 | ₹22.25 | ₹19.40 | ₹19.50 | -12.36% | |
| ₹22.57 | ₹23.50 | ₹16.85 | ₹23.50 | +4.12% | |
| ₹23.94 | ₹29.00 | ₹22.57 | ₹23.68 | -1.09% | |
| ₹23.05 | ₹29.00 | ₹21.65 | ₹23.47 | +1.82% | |
| ₹22.03 | ₹27.15 | ₹21.80 | ₹24.26 | +10.12% | |
| ₹25.54 | ₹26.98 | ₹23.18 | ₹23.18 | -9.24% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vanta Bioscience Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vanta Bioscience Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VANTABIO across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (240.88%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (357.58%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (72.81%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
11 factors identified
Below-Average Return on Equity (0.70%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (1.19%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-2.92%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 163.55x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (-28.62% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-26.00% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-24.21% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Elevated Debt Levels (D/E: 1.80)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (1.01x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-40.26 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vanta Bioscience Ltd vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Vanta Bioscience Ltd with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Vanta Bioscience LtdVanta Bioscienc...Selected✓ VANTABIO • 540729 | 23.9/100 | ₹25.29₹25 | ₹17.99₹17.99 | 163.55Average 163.6 Average | 0.70%Poor 0.70% Poor | 1.19%Poor 1.19% Poor | 1.80Average 1.8 Average | -24.21%Poor -24.21% Poor | -28.62%Poor -28.62% Poor | 0.00% |
Syngene International LtdSyngene Interna... SYNGENE • 539268 | 35.4/100 | ₹385.90₹386 | ₹16982.38₹16982.38 | 47.13Average 47.1 Average | 7.71%Poor 7.71% Poor | 9.91%Poor 9.91% Poor | 0.04Excellent 0.0 Excellent | -0.98%Poor -0.98% Poor | 9.45%Good 9.45% Good | 0.30% |
Indegene LtdIndegene Ltd... INDGN • 544172 | 57/100 | ₹515.15₹515 | ₹12302.12₹12302.12 | 29.67Average 29.7 Average | 14.41%Average 14.41% Average | 18.82%Good 18.82% Good | 0.05Excellent 0.1 Excellent | 23.02%Excellent 23.02% Excellent | 29.44%Excellent 29.44% Excellent | 0.39% |
Suven Life Sciences LtdSuven Life Scie... SUVEN • 530239 | 11.4/100 | ₹307.10₹307 | ₹10067.84₹10067.84 | — — | -78.80%Poor -78.80% Poor | -76.92%Poor -76.92% Poor | 0.03Excellent 0.0 Excellent | — — | -12.01%Poor -12.01% Poor | 0.00% |
Vimta Labs LtdVimta Labs Ltd... VIMTALABS • 524394 | 63.6/100 | ₹608.85₹609 | ₹2555.98₹2555.98 | 32.42Average 32.4 Average | 18.87%Good 18.87% Good | 25.23%Excellent 25.23% Excellent | 0.01Excellent 0.0 Excellent | 29.96%Excellent 29.96% Excellent | 14.27%Good 14.27% Good | 0.35% |
Take Solutions LtdTake Solutions ... TAKE • 532890 | 31.2/100 | ₹21.42₹21 | ₹304.13₹304.13 | 71.39Average 71.4 Average | 16.53%Good 16.53% Good | 18.51%Good 18.51% Good | 0.00Excellent 0.0 Excellent | 15.08%Excellent 15.08% Excellent | -41.25%Poor -41.25% Poor | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 56.9/100 | ₹69.49₹69 | ₹199.32₹199.32 | 77.86Average 77.9 Average | 8.00%Poor 8.00% Poor | 9.98%Poor 9.98% Poor | 0.09Excellent 0.1 Excellent | 22.72%Excellent 22.72% Excellent | 151.69%Excellent 151.69% Excellent | 0.00% |
Bilcare LtdBilcare Ltd... BI • 526853 | 28.9/100 | ₹58.17₹58 | ₹147.94₹147.94 | 26.80Average 26.8 Average | 1.66%Poor 1.66% Poor | 5.56%Poor 5.56% Poor | 3.15Poor 3.1 Poor | 16.32%Excellent 16.32% Excellent | 3.33%Average 3.33% Average | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 24.6/100 | ₹16.30₹16 | ₹24.53₹24.53 | 19.47Average 19.5 Average | 3.35%Poor 3.35% Poor | 5.21%Poor 5.21% Poor | 0.16Excellent 0.2 Excellent | -6.68%Poor -6.68% Poor | -3.19%Poor -3.19% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Ltd share price16982.38 Cr
- Indegene Ltd share price12302.12 Cr
- Suven Life Sciences Ltd share price10067.84 Cr
- Vimta Labs Ltd share price2555.98 Cr
- Take Solutions Ltd share price304.13 Cr
Vanta Bioscience Ltd Quarterly Performance
Latest quarterly metrics for VANTABIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
357.58%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
240.88%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-28.62%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-24.21%
Compounded annual net profit growth over 5 years
Vanta Bioscience Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VANTABIO — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Vanta Bioscience Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Vanta Bioscience Ltd (VANTABIO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Vanta Bioscience Ltd
About VANTABIO (Vanta Bioscience Ltd)
Vanta Bioscience Ltd is a cutting-edge healthcare research organization dedicated to accelerating drug discovery and development through advanced analytics and innovative technolog...ies. We provide comprehensive preclinical research services, leveraging state-of-the-art facilities and a team of expert scientists to deliver robust and reliable data. Our expertise spans a wide range of disciplines, including molecular biology, pharmacology, toxicology, and bioanalysis. By integrating sophisticated analytical tools with deep scientific knowledge, we empower our clients to make informed decisions, optimize their research strategies, and ultimately bring life-changing therapies to market faster. At Vanta Bioscience, we are committed to delivering excellence at every stage of the preclinical research process. Our services include specialized assay development, validation, and execution of in vitro and in vivo studies, tailored to meet the unique needs of our clients. We utilize advanced techniques such as genomics, proteomics, and metabolomics to gain deeper insights into disease mechanisms and drug action. Furthermore, we offer comprehensive regulatory support, ensuring compliance with international guidelines and standards. Our goal is to be a trusted partner for pharmaceutical, biotechnology, and agrochemical companies, enabling them to overcome scientific challenges and achieve their research goals. Vanta Bioscience leverages its unique combination of scientific expertise, technological innovation, and rigorous quality control to provide actionable insights for our clients. We believe in the power of data-driven decision-making and continually invest in cutting-edge technologies to enhance our capabilities. From target identification to lead optimization, we offer a complete suite of services to support the entire preclinical drug development pipeline. By partnering with Vanta Bioscience, our clients gain access to a world-class research team, advanced analytical tools, and a commitment to delivering high-quality results that accelerate the development of innovative healthcare solutions.
Company Details
Key Leadership
VANTABIO Share Price: Frequently Asked Questions
What is the current share price of Vanta Bioscience Ltd?
Vanta Bioscience Ltd (VANTABIO) trades at ₹25.29 on NSE and BSE. Market cap ₹17.99 (Cr). Educational data only.
What is the P/E ratio of Vanta Bioscience Ltd?
Vanta Bioscience Ltd has a P/E of 163.55x vs industry average 39.78x.
What is the Bull Run score for Vanta Bioscience Ltd?
Vanta Bioscience Ltd has a Bull Run score of 23.9/100 based on 25+ financial parameters.
Does Vanta Bioscience Ltd pay dividends?
Vanta Bioscience Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Vanta Bioscience Ltd?
Vanta Bioscience Ltd has ROE of 0.70%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vanta Bioscience Ltd?
Vanta Bioscience Ltd has debt-to-equity of 1.80.
Is Vanta Bioscience Ltd a good investment?
Bull Run gives Vanta Bioscience Ltd a score of 23.9/100. This is not investment advice — consult a SEBI-registered advisor.